Besides Covaxin, Bharat Biotech has been actively engaged on growing one other vaccine, for which it tied up with Washington University School of Medicine in St Louis for the novel “chimp-adenovirus” (Chimpanzee adenovirus), a single dose intranasal vaccine for Covid-19.
“BBV154 (intranasal Covid-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. These studies have been conducted in the USA and India. Phase I human clinical trials will commence during Feb-March 2021,” an e mail reply from the city-based vaccine maker advised P T I.
Phase I human medical trials will probably be performed in India, Bharat Biotech added.
The Phase-1 trials will probably be performed in Saint Louis University’s Vaccine and Treatment Evaluation Unit, the corporate sources mentioned including Bharat Biotech owns the rights to distribute the vaccine in all markets besides USA, Japan and Europe.
Krishna Ella, Chairman of Bharat Biotech had earlier mentioned the corporate is specializing in the intranasal vaccine as the present vaccines require two dose intramuscular injections and a rustic like India wants 2.6 billion syringes and needles which can add as much as air pollution.
An intranasal vaccine won’t solely be easy to manage however scale back the usage of medical consumables similar to needles, syringes, and so on., considerably impacting the general value of a vaccination drive, he had mentioned.
“One drop of vaccine in each of the nostrils is sufficient,” he had mentioned.
According to him, maintaining a number of points in thoughts Bharat Biotech tied up with Washington University School of Medicine for the only dose intranasal vaccine for Covid-19.
He had mentioned Bharat Biotech envisions that it will scale this vaccine to at least one billion doses, translating into equal variety of people being vaccinated receiving a single-dose routine.
Bharat Biotech, upon acquiring required regulatory approval, will pursue additional phases of medical trials in India and undertake massive scale manufacture of the vaccine at its GMP (good manufacturing follow) facility situated in Genome Valley, right here, the corporate had earlier mentioned.
The intranasal vaccine candidate has proven unprecedented ranges of safety in mice research and the expertise and information having been already revealed within the prestigious scientific journal ‘Cell’ and in an editorial in ‘Nature’, the corporate had mentioned.
Bharat Biotech has efficiently accomplished enrollment of25,800 volunteers for the Phase-Three trials of its Covid-19 vaccine Covaxin.